Pre-analytical effects of blood sampling and handling in quantitative immunoassays for rheumatoid arthritis

Journal of Immunological Methods

Volumn 378, Issue 1-2, 2012, Pages 72-80

  Zhao, Xiaoyan ^a   Qureshi, Ferhan ^a   Eastman, P Scott ^a   Manning, William C ^a   Alexander, Claire ^a   Robinson, William H ^b   Hesterberg, Lyndal K ^a  

^a Crescendo Bioscience Inc   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoantibody; Blood sampling methods; Multiplex immunoassay; Protein biomarker; Rheumatoid arthritis; Serum handling methods

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LEPTIN; PLASMA PROTEIN; RESISTIN; STROMELYSIN; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A;

ANALYTICAL PARAMETERS; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BLOOD STORAGE; CENTRIFUGATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENVIRONMENTAL TEMPERATURE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LABORATORY DIAGNOSIS; METHODOLOGY; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SERUM; SHIPPING;

ALGORITHMS; AMINO ACID SEQUENCE; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD SPECIMEN COLLECTION; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOASSAY; MOLECULAR SEQUENCE DATA; PROTEINS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SPECIMEN HANDLING;

EID: 84862812025     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.02.007     Document Type: Article

References (32)

1. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31:315.
2. Chandra P.E., Sokolove J., Hipp B.G., Lindstrom T.M., Elder J.T., Reveille J.D., Eberl H., Klause U., Robinson W.H. Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res. Ther. 2011, 13:R102.
3. Curtis J.R., Haney D., Van der Helm A.H., Shen Y., Knevel R., Cavet G., Dirven L. Validation of a multi-biomarker test for rheumatoid arthritis (RA) disease activity (Vectra DA) in a multi-cohort study. Arthritis Rheum. 2010, 62(Suppl. 10):1782.
4. Dancey J.E., Dobbin K.K., Groshen S., Jessup J.M., Hruszkewycz A.H., Koehler M., Parchment R., Ratain M.J., Shankar L.K., Stadler W.M., True L.D., Gravell A., Grever M.R. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 2010, 16:1745.
5. Eastman S., Manning B., Qureshi F., Cavet G., Haney D., Shen Y., Alexander C., Fleischmann R., Hesterberg L.K. Assay development for precise measurement of disease activity serum biomarkers. Ann. Rheum. Dis. 2010, 69(Suppl. 3):170.
6. Ellington A.A., Kullo I.J., Bailey K.R., Klee G.G. Measurement and quality control issues in multiplex protein assays: a case study. Clin. Chem. 2009, 55:1092.
7. Ellington A.A., Kullo I.J., Bailey K.R., Klee G.G. Antibody-based protein multiplex platforms: technical and operational challenges. Clin. Chem. 2010, 56:186.
8. FDA Guidance for Industry Bioanalytical Method Validation 2001, Food and Drug Administration.
9. Findlay J.W., Dillard R.F. Appropriate calibration curve fitting in ligand binding assays. AAPS J. 2007, 9:E260.
10. Gerszten R.E., Accurso F., Bernard G.R., Caprioli R.M., Klee E.W., Klee G.G., Kullo I., Laguna T.A., Roth F.P., Sabatine M., Srinivas P., Wang T.J., Ware L.B. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295:L16.
11. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J., Hazes J.M., Zwinderman A.H., Ronday H.K., Han K.H., Westedt M.L., Gerards A.H., van Groenendael J.H., Lems W.F., van Krugten M.V., Breedveld F.C., Dijkmans B.A. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005, 52:3381.
12. Graudal N.A., Jurik A.G., de Carvalho A., Graudal H.K. Radiographic progression in rheumatoid arthritis: a long-term prospective study of 109 patients. Arthritis Rheum. 1998, 41:1470.
13. Grigor C., Capell H., Stirling A., McMahon A.D., Lock P., Vallance R., Kincaid W., Porter D. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004, 364:263.
14. Hueber W., Kidd B.A., Tomooka B.H., Lee B.J., Bruce B., Fries J.F., Sonderstrup G., Monach P., Drijfhout J.W., van Venrooij W.J., Utz P.J., Genovese M.C., Robinson W.H. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2005, 52:2645.
15. Hueber W., Tomooka B.H., Zhao X., Kidd B.A., Drijfhout J.W., Fries J.F., van Venrooij W.J., Metzger A.L., Genovese M.C., Robinson W.H. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann. Rheum. Dis. 2007, 66:712.
16. Inoue E., Yamanaka H., Hara M., Tomatsu T., Kamatani N. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann. Rheum. Dis. 2007, 66:407.
17. Karlson E.W., Chibnik L.B., Cui J., Plenge R.M., Glass R.J., Maher N.E., Parker A., Roubenoff R., Izmailova E., Coblyn J.S., Weinblatt M.E., Shadick N.A. Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann. Rheum. Dis. 2008, 67:358.
18. Miles R.R., Roberts R.F., Putnam A.R., Roberts W.L. Comparison of serum and heparinized plasma samples for measurement of chemistry analytes. Clin. Chem. 2004, 50:1704.
19. Neumann E.J., Bonistalli K.N. Effect of blood sample handling post-collection on Erysipelothrix rhusiopathiae antibody titres. Vet. J. 2009, 180:325.
20. Osborn L., Hession C., Tizard R., Vassallo C., Luhowskyj S., Chi-Rosso G., Lobb R. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989, 59:1203.
21. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J. Clin. Invest. 2003, 111:1805.
22. Prevoo M.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38:44.
23. Rai A.J., Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev. Proteomics 2006, 3:409.
24. Rantapaa-Dahlqvist S., de Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., Sundin U., van Venrooij W.J. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48:2741.
25. Rioja I., Hughes F.J., Sharp C.H., Warnock L.C., Montgomery D.S., Akil M., Wilson A.G., Binks M.H., Dickson M.C. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008, 58:2257.
26. Scott D.L., Steer S. The course of established rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2007, 21:943.
27. Sturgeon C., Hill R., Hortin G.L., Thompson D. Taking a new biomarker into routine use-a perspective from the routine clinical biochemistry laboratory. Proteomics Clin. Appl. 2010, 4:892.
28. Tuck M.K., Chan D.W., Chia D., Godwin A.K., Grizzle W.E., Krueger K.E., Rom W., Sanda M., Sorbara L., Stass S., Wang W., Brenner D.E. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J. Proteome Res. 2009, 8:113.
29. Uhlar C.M., Whitehead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 1999, 265:501.
30. van der Pouw Kraan T.C., van Gaalen F.A., Kasperkovitz P.V., Verbeet N.L., Smeets T.J., Kraan M.C., Fero M., Tak P.P., Huizinga T.W., Pieterman E., Breedveld F.C., Alizadeh A.A., Verweij C.L. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 2003, 48:2132.
31. Verstappen S.M., Jacobs J.W., van der Veen M.J., Heurkens A.H., Schenk Y., ter Borg E.J., Blaauw A.A., Bijlsma J.W. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann. Rheum. Dis. 2007, 66:1443.
32. Wener M.H. Multiplex, megaplex, index, and complex: the present and future of laboratory diagnostics in rheumatology. Arthritis Res. Ther. 2011, 138:134.